Last Updated: 02/12/2024
Safety and immunogenicity of novel vaccination schedules with malaria vaccines ChAd63 ME-TRAP and MVA ME-TRAP
Objectives
The aim of this study is to assess the safety and immunogenicity of novel schedules for vaccination with the candidate malaria vaccines AdCh63 ME-TRAP and MVA ME-TRAP.
These vaccines have been evaluated previously in a number of clinical trials and proved to be safe and capable of inducing a protective cellular immune response following challenges with the parasite. All volunteers recruited will be healthy adults. They will be primed with AdCh63 ME-TRAP administered intramuscularly and boosted several times with AdCh63 ME-TRAP and MVA ME-TRAP according to various schedules. Safety data will be collected for each of the seven regimens. The secondary aim of this study will be to assess the immune responses generated by each of these regimes.
Study type: Interventional
Enrollment: 39 participants
Primary purpose: Prevention
Allocation:Non-Randomized
Interventional Model: Parallel assignment
Masking :Open label
NCT number: NCT01364883
Phase: Phase I
Related Resources
